Table 3. Number of subjects who reported injection site reactions*.
Pain | Tenderness | Erythema | Swelling | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
IM | ID | IM | ID | IM | ID | IM | ID | ||||
(n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | (n = 10) | ||||
Grade 1 | 1 | 4 | 3 | - | - | 7 | - | 1 | |||
Grade 2 | - | 2 | 4 | - | - | 1 | - | - | |||
Grade 3 | - | - | - | - | - | - | - | - | |||
Grade 4 | - | - | - | - | - | - | - | - |
In accordance with FDA toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.